SCHEMBL24254522

SCHEMBL24254522

Cc1ccc(S(=O)(=O)NCc2ccccc2)cc1N

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.63
CA9 Q16790 2/20 0.63
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
ATM Q13315 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
KEAP1 Q14145 1/20 0.58
POLB P06746 3/20 0.57
LMNA P02545 1/20 0.57
SLC12A2 P55011 1/20 0.57
SLC12A5 Q9H2X9 1/20 0.57
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
ALDH1A1 P00352 4/20 0.55
PKM P14618 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CYP19A1 P11511 2/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
HPGD P15428 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19400889 0.86 NPC1 (0.73) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL5952598 0.86 KEAP1 (0.64) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL2499052 0.82 PKM (0.69) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL31689615 0.82 CA12 (0.63) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL16599379 0.80 CA12 (0.60) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL29956424 0.80 CA12 (0.60) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL9037802 0.80 CA12 (0.60) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL117930 0.79 PKM (0.65) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL28836851 0.79 PKM (0.65) CA12CA9CYP1A2CYP3A4ATM
SCHEMBL19197973 0.79 SMN1; SMN2 (0.69) CA12CA9CYP1A2CYP3A4ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 CA12 1338/4885CA9 1988/4885CYP1A2 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.